Literature DB >> 698398

Activation of factor X by factors IXa and VIII; a specific assay for factor IXa in the presence of thrombin-activated factor VIII.

M B Hultin, Y Nemerson.   

Abstract

We studied the activation of factor X by the intrinsic pathway of blood coagulation using a new assay of factor X activation. When factor X tritiated in its sialic acid residues is activated, activation can be measured by the release of tritiated activation peptide, and the initial rate of activation can be determined under varying conditions. In the presence of phospholipid and calcium ions, factor IXa activated factor X slowly without factor VIII, and this activation was blocked by a specific factor IX inhibitor. These data provide strong evidence that factor IXa is the enzyme responsible for factor X activation by the intrinsic pathway. The role of factor VIII was also investigated. Factor VIII could be reproducibly thrombin activated and then stabilized by the addition of 2 mM benzamidine hydrochloride; this suggests that inactivation is due to proteolysis. Neither unactivated nor thrombin-activated factor VIII produced factor X activation without factor IXa. With a constant level of factor IXa, factor X activation was directly proportional to the level of activated factor VIII. With a constant level of activated factor VIII, factor X activation was proportional to the factor IXa concentration. This observation was exploited to develop a specific, sensitive assay for factor IXa.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 698398

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  10 in total

1.  Hemophilia A due to mutations that create new N-glycosylation sites.

Authors:  A M Aly; M Higuchi; C K Kasper; H H Kazazian; S E Antonarakis; L W Hoyer
Journal:  Proc Natl Acad Sci U S A       Date:  1992-06-01       Impact factor: 11.205

2.  Structural model of porcine factor VIII and factor VIIIa molecules based on scanning transmission electron microscope (STEM) images and STEM mass analysis.

Authors:  M W Mosesson; D N Fass; P Lollar; J P DiOrio; C G Parker; G J Knutson; J F Hainfeld; J S Wall
Journal:  J Clin Invest       Date:  1990-06       Impact factor: 14.808

3.  Role of human factor VIII in factor X activation.

Authors:  M B Hultin
Journal:  J Clin Invest       Date:  1982-04       Impact factor: 14.808

4.  Factor VIII-East Hartford (arginine 1689 to cysteine) has procoagulant activity when separated from von Willebrand factor.

Authors:  A M Aly; L W Hoyer
Journal:  J Clin Invest       Date:  1992-05       Impact factor: 14.808

5.  Hemophilia as a defect of the tissue factor pathway of blood coagulation: effect of factors VIII and IX on factor X activation in a continuous-flow reactor.

Authors:  D Repke; C H Gemmell; A Guha; V T Turitto; G J Broze; Y Nemerson
Journal:  Proc Natl Acad Sci U S A       Date:  1990-10       Impact factor: 11.205

6.  Cleavage of human high molecular weight kininogen markedly enhances its coagulant activity. Evidence that this molecule exists as a procofactor.

Authors:  C F Scott; L D Silver; M Schapira; R W Colman
Journal:  J Clin Invest       Date:  1984-04       Impact factor: 14.808

7.  The contribution of Ca2+ and phospholipids to the activation of human blood-coagulation Factor X by activated Factor IX.

Authors:  K Mertens; R M Bertina
Journal:  Biochem J       Date:  1984-11-01       Impact factor: 3.857

8.  The contributions of Ca2+, phospholipids and tissue-factor apoprotein to the activation of human blood-coagulation factor X by activated factor VII.

Authors:  V J Bom; R M Bertina
Journal:  Biochem J       Date:  1990-01-15       Impact factor: 3.857

9.  Localization of the binding regions of a murine monoclonal anti-factor VIII antibody and a human anti-factor VIII alloantibody, both of which inhibit factor VIII procoagulant activity, to amino acid residues threonine351-serine365 of the factor VIII heavy chain.

Authors:  P A Foster; C A Fulcher; R A Houghten; S de Graaf Mahoney; T S Zimmerman
Journal:  J Clin Invest       Date:  1988-07       Impact factor: 14.808

10.  Characterization of three abnormal factor IX variants (Bm Lake Elsinore, Long Beach, and Los Angeles) of hemophilia-B. Evidence for defects affecting the latent catalytic site.

Authors:  P Usharani; B J Warn-Cramer; C K Kasper; S P Bajaj
Journal:  J Clin Invest       Date:  1985-01       Impact factor: 14.808

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.